UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
“We are proud to have been one of the top performing IPOs of 2017 in the biotech space and look forward to more achievements in the future – including bringing transformative uro-oncology treatments to patients,” said
A live webcast of the ceremony will be available at https://livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx from approximately
About UroGen Pharma Ltd.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the timing and results of clinical development of UGN-101 (MitoGel), timing and expectations of results from the OLYMPUS trial, and the prospective trading results of UroGen’s ordinary shares, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials and potential complications thereof, including with respect to enrollment; the ability to obtain and maintain regulatory approval; and market risks. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of our annual report for the year ended December 31, 2017 filed with the SEC on March 15, 2018 and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.